Search Within

Eric C Haupt

Formats
  1. Meeting Abstract (8)
Groups
  1. Department of Medicine (7)
  2. GSK Faculty (7)
  3. Genitourinary Oncology Service (7)
  4. Molecular Imaging and Therapy Service (7)
  5. Molecular Pharmacology and Chemistry Program Faculty (7)
  6. Radiology, Department of (7)

More Groups

People
  1. Howard Scher (7)
  2. Michael Morris (7)
  3. Steven Larson (7)
  4. Heiko Schoder (6)
  5. Josef Fox (6)
  6. John Humm (4)

More People

Years
  1. 2022 (1)
  2. 2013 (3)
  3. 2012 (2)
  4. 2011 (2)
Publications
  1. Journal of Clinical Oncology (8)
Publishers
  1. American Society of Clinical Oncology (8)

Results (8)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Real-world risk-stratified cancer survivorship pathways
    Meeting Abstract

    Hahn, E. E.; Chen, A.; Haupt, E. C.; Lyons, L. J.; Habeshian, T.; Munoz-Plaza, C. E.; Shen, E.; Nguyen, H. Q.; Gould, M. K.; Ferreira, A.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Phase I trial of zirconium 89 (Zr89) radiolabeled J591 in metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Morris, M. J.; Pandit-Taskar, N.; Carrasquillo, J. A.; O'Donoghue, J. A.; Humm, J.; Lyashchenko, S. K.; Haupt, E. C.; Bander, N. H.; Tagawa, S. T.; Holland, J. P.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Post-treatment alterations in 18F-dihydrotestosterone (FDHT) and FDG PET/CT in metastatic castration-resistant prostate cancer (mCRPC) treated with cabozantinib
    Meeting Abstract

    Fox, J. J.; Haupt, E. C.; Humm, J.; Autio, K. A.; Rathkopf, D. E.; Vargas, H. A.; Schöder, H.; Hricak, H.; Larson, S. M.; Scher, H. I.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Evaluating 18F-16B-fluoro-5α-dihydrotestosterone (FDHT) and FDG-PET as a measure of disease progression in metastatic castration resistant prostate cancer (mCRPC)
    Meeting Abstract

    Autio, K. A.; Fox, J. J.; Schneider, C. W.; Schöder, H.; Humm, J.; Rathkopf, D. E.; Slovin, S. F.; Danila, D. C.; Haupt, E. C.; Larson, S. M.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • 18F-16 beta-fluoro-5 alpha-dihydrotestosterone (FDHT) PET as a prognostic biomarker for survival in patients with metastatic castrate-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Autio, K. A.; Fox, J. J.; Jia, X.; Heller, G.; Schoder, H.; Humm, J.; Haupt, E. C.; Schneider, C.; Scher, H. I.; Larson, S. M.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Comparison of PSA, FDG-PET, and Prostate Cancer Working Group 2 (PCWG2) criteria to interpret apparent progression on first post-treatment bone scan
    Meeting Abstract

    Autio, K. A.; Fox, J. J.; Haupt, E. C.; Schoder, H.; Scher, H. I.; Larson, S. M.; Morris, M. J.
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • The PCCTC imaging data capture toolset: An analysis of its impact on prostate cancer clinical trial accuracy and workload
    Meeting Abstract

    Dennis, E. R.; Fox, J. J.; Larson, S. M.; Farrelly, J. S.; Schwartz, L. H.; Schöder, H.; Haupt, E. C.; Borwick, L. S.; Scher, H. I.; Morris, M. J.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • The Prostate Cancer Clinical Trials Consortium (PCCTC) bone scan data capture tool for clinical trials using Prostate Cancer Working Group 2 (PCWG2) criteria: Effect on data accuracy and workload
    Meeting Abstract

    Morris, M. J.; Farrelly, J. S.; Fox, J. J.; Dennis, E. R.; Schwartz, L. H.; Schoder, H.; Haupt, E. C.; Borwick, L. S.; Larson, S. M.; Scher, H. I.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save